Pharmacologic treatment of spasticity in children

Ann Tilton, Jilda Vargus-Adams, Mauricio R. Delgado

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Many clinicians frequently face the dilemma of whether and how to medically treat spasticity. When pharmacologic intervention is deemed appropriate, treatment decisions must first be based on accurate assessment using valid and reliable clinical instruments, and, importantly, specific, measurable, achievable, and realistic treatment goals should be delineated. For the treatment of localized or segmental spasticity, botulinum toxin (BoNT-A) is recommended as an effective and generally safe treatment. For more generalized spasticity, a number of useful oral agents and intrathecal baclofen are available, each with their positive and negative attributes. Fundamental knowledge of pharmacologic properties and toxicities of these medications is required for safe and appropriate use. To achieve optimum results, spasticity treatment should be part of an integrated therapeutic approach in which patients, caregivers, therapists, physicians, and surgeons have an open and clear communication about the overall rehabilitation process of the patient. This review summarizes the current pharmacologic approaches to spasticity treatment in children, critically evaluating published studies in the context of established evidence-based criteria.

Original languageEnglish (US)
Pages (from-to)261-267
Number of pages7
JournalSeminars in Pediatric Neurology
Volume17
Issue number4
DOIs
StatePublished - Dec 2010

Fingerprint

Therapeutics
Baclofen
Botulinum Toxins
Caregivers
Rehabilitation
Communication
Physicians
incobotulinumtoxinA
Surgeons

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Pharmacologic treatment of spasticity in children. / Tilton, Ann; Vargus-Adams, Jilda; Delgado, Mauricio R.

In: Seminars in Pediatric Neurology, Vol. 17, No. 4, 12.2010, p. 261-267.

Research output: Contribution to journalArticle

Tilton, Ann ; Vargus-Adams, Jilda ; Delgado, Mauricio R. / Pharmacologic treatment of spasticity in children. In: Seminars in Pediatric Neurology. 2010 ; Vol. 17, No. 4. pp. 261-267.
@article{f9bca3a163414ee7a74a6830721a69d6,
title = "Pharmacologic treatment of spasticity in children",
abstract = "Many clinicians frequently face the dilemma of whether and how to medically treat spasticity. When pharmacologic intervention is deemed appropriate, treatment decisions must first be based on accurate assessment using valid and reliable clinical instruments, and, importantly, specific, measurable, achievable, and realistic treatment goals should be delineated. For the treatment of localized or segmental spasticity, botulinum toxin (BoNT-A) is recommended as an effective and generally safe treatment. For more generalized spasticity, a number of useful oral agents and intrathecal baclofen are available, each with their positive and negative attributes. Fundamental knowledge of pharmacologic properties and toxicities of these medications is required for safe and appropriate use. To achieve optimum results, spasticity treatment should be part of an integrated therapeutic approach in which patients, caregivers, therapists, physicians, and surgeons have an open and clear communication about the overall rehabilitation process of the patient. This review summarizes the current pharmacologic approaches to spasticity treatment in children, critically evaluating published studies in the context of established evidence-based criteria.",
author = "Ann Tilton and Jilda Vargus-Adams and Delgado, {Mauricio R.}",
year = "2010",
month = "12",
doi = "10.1016/j.spen.2010.10.009",
language = "English (US)",
volume = "17",
pages = "261--267",
journal = "Seminars in Pediatric Neurology",
issn = "1071-9091",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Pharmacologic treatment of spasticity in children

AU - Tilton, Ann

AU - Vargus-Adams, Jilda

AU - Delgado, Mauricio R.

PY - 2010/12

Y1 - 2010/12

N2 - Many clinicians frequently face the dilemma of whether and how to medically treat spasticity. When pharmacologic intervention is deemed appropriate, treatment decisions must first be based on accurate assessment using valid and reliable clinical instruments, and, importantly, specific, measurable, achievable, and realistic treatment goals should be delineated. For the treatment of localized or segmental spasticity, botulinum toxin (BoNT-A) is recommended as an effective and generally safe treatment. For more generalized spasticity, a number of useful oral agents and intrathecal baclofen are available, each with their positive and negative attributes. Fundamental knowledge of pharmacologic properties and toxicities of these medications is required for safe and appropriate use. To achieve optimum results, spasticity treatment should be part of an integrated therapeutic approach in which patients, caregivers, therapists, physicians, and surgeons have an open and clear communication about the overall rehabilitation process of the patient. This review summarizes the current pharmacologic approaches to spasticity treatment in children, critically evaluating published studies in the context of established evidence-based criteria.

AB - Many clinicians frequently face the dilemma of whether and how to medically treat spasticity. When pharmacologic intervention is deemed appropriate, treatment decisions must first be based on accurate assessment using valid and reliable clinical instruments, and, importantly, specific, measurable, achievable, and realistic treatment goals should be delineated. For the treatment of localized or segmental spasticity, botulinum toxin (BoNT-A) is recommended as an effective and generally safe treatment. For more generalized spasticity, a number of useful oral agents and intrathecal baclofen are available, each with their positive and negative attributes. Fundamental knowledge of pharmacologic properties and toxicities of these medications is required for safe and appropriate use. To achieve optimum results, spasticity treatment should be part of an integrated therapeutic approach in which patients, caregivers, therapists, physicians, and surgeons have an open and clear communication about the overall rehabilitation process of the patient. This review summarizes the current pharmacologic approaches to spasticity treatment in children, critically evaluating published studies in the context of established evidence-based criteria.

UR - http://www.scopus.com/inward/record.url?scp=78650290311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650290311&partnerID=8YFLogxK

U2 - 10.1016/j.spen.2010.10.009

DO - 10.1016/j.spen.2010.10.009

M3 - Article

C2 - 21183133

AN - SCOPUS:78650290311

VL - 17

SP - 261

EP - 267

JO - Seminars in Pediatric Neurology

JF - Seminars in Pediatric Neurology

SN - 1071-9091

IS - 4

ER -